Recap: Biohaven Pharmaceutical Q3 Earnings

 

Shares of Biohaven Pharmaceutical BHVN traded flat in pre-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share decreased 30.88% year over year to ($2.67), which beat the estimate of ($2.89).

Revenue of $17,664,000 up by 0.00% year over year, which missed the estimate of $19,840,000.

Outlook

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

Details Of The Call

Date: Nov 09, 2020

Time: 08:30 AM

ET Webcast URL: https://78449.themediaframe.com/dataconf/productusers/bhvn/mediaframe/41093/indexl.html

Recent Stock Performance

52-week high: $89.46

Company's 52-week low was at $26.56

Price action over last quarter: Up 40.88%

Company Profile

Biohaven Pharmaceutical Holding Co Ltd is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipeline products include BHV3000-301, BHV3000-302, BHV3000-303, and others.

Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNews
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...